This week on 'The Top Line,' we're diving into the details of the spree of big-money biopharma deals in 2023 and examining what that means for this year.Fierce Pharma Senior Writer Kevin Dunleavy sits down with Cody Powers, a consultant who advises companies on business development and franchise growth strategy, to discuss the reasons behind the numerous high-value deals in 2023, which companies are primed to make major moves this year, and whether the trend of acquiring ADCs and obesity treatments will continue. To learn more about the topics in this episode: The top 10 biopharma M&A deals of 20232024 forecast: M&A saw an uptick in 2023.

本周，在《顶线》上，我们将深入了解2023年大规模生物制药交易的细节，并研究这对今年意味着什么。《凶猛制药》资深作家凯文·邓利维（KevinDunleavy）与科迪·鲍尔斯（CodyPowers）坐在一起，科迪·鲍尔斯是一位顾问，他为公司的业务发展和特许经营增长战略提供咨询，讨论2023年众多高价值交易背后的原因，这些公司今年准备采取重大行动，以及收购ADC和肥胖治疗的趋势是否会继续。要了解更多有关本集主题的信息：20232024年10大生物制药并购交易预测：2023年并购出现上升。

Analysts expect the trend to continueFor biopharma M&A, the best returns come from small deals: analysts.

分析师们预计，生物制药并购的趋势将持续下去，最好的回报来自于小额交易：分析师们。